Full text PDF - International Policy Network

Sources 2914 The diseases of poverty and the 10/90 gapAttaran, A., Barnes, K., Curtis, C., d’Alessandro, U., Fanello, C., Galinski, M., Kokwaro,G., Looareesuwan, S., Makanga, M., Mutabingwa, T., (2004), “WHO, the GlobalFund, and medical malpractice in malaria treatment,” The Lancet, 363:9404, pp237–240.Barat, L., Palmer, N., Basu, S., Worrall, E., Hanson, K., Mills, A., (2003), “Do MalariaControl Interventions Reach the Poor?: A view Through the Equity Lens,” DiseaseControl Priorities Project, Bethesda: National Institutes of Health.Black, RE., Where and why are 10 million children dying every year? The Lancet 2003;361: 2226–34Bruce, N., Perez-Padilla, R. & Albalak, R., (2002), “The health effects of indoor airpollution exposure in developing countries”, Geneva: World HealthOrganization.Carrin, G., (2002), “Social Health Insurance in developing countries: a continuingchallenge,” International Social Security Review, Vol. 55.Chima, R., Goodman, C. & Mills, A., (2003), “The economic impact of malaria inAfrica: a critical review of the evidence,” Health Policy, 63(1): 17–36Deolalikar, A., (1995), “Government Health Spending in Indonesia: Impact onChildren in Different Economic Groups.” In Public Spending and the Poor: Theoryand Evidence, eds. Van de Walle, D., & Nead, K., Baltimore: John HopkinsUniversity Press.Department of Health and Human Services, United States, (2002), “Report to thePresident: Prescription drug coverage, spending, utilization, and prices”, April2002.de Soto, H., (2001), The Mystery of Capital, London: Bantam Books.Fenwick, A, (2006), “Waterborne Infectious Diseases – Could They Be Consigned toHistory?” Science, 313:5790, pp 1077 – 1081Filmer, D. & Pritchett, L., (1999), “The Impact of public spending on health: doesmoney matter?” World BankFilmer, D., Hammer, J., Pritchett, L., (2000), “Weak links in the chain: a diagnosis ofhealth policy in poor countries,” World Bank Research Observer, 15(2): 199–224.Jones, G., & Stetekee R., (2004), How many child deaths can we prevent this year? TheLancet, vol 362, 5 July 2004Kumarasamy, N., (2004), “Generic antiretroviral drugs – will they be the answer toHIV in the developing world?” The Lancet, vol 364.Levison, L. & Laing, R., (2003), “The hidden costs of essential medicines,” WHOessential drugs monitor, Issue 33.Levison, L., (2003), “Policy and programming options for reducing the procurementcosts of essential medicines in developing countries”, concentration paper:Boston University School of Public Health.Love J., Hubbard T., (2003) “An agenda for research and development,” Meeting onthe role of generics and local industry in attaining the Millennium DevelopmentGoals in pharmaceuticals and vaccines. World Bank: Washington DC, June 2003Monath, T., (2005), “Yellow Fever Vaccine,” Expert Review of Vaccines, 4(4):553–74Medecins Sans Frontiers & Drugs for Neglected Diseases Working Group, (2001),“Fatal Imbalance: The Crisis in Research and Development for Drugs for